Skip to content
Bored Studies
Recruiting

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

i-Lumen Scientific AUS PTY LTD · with i-Lumen Scientific, Inc. · NCT06662162

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 60+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Not applicable
Target enrollment
100
US sites recruiting
6
Study start
May 7, 2025
Record last updated
August 26, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.

Participants will

  • Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months.
  • Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.

Being studied: i-Lumen AMD

Conditions: Age-Related Macular Degeneration; Age-related Macular Degeneration (ARMD); Intermediate AMD; Geographic Atrophy Secondary to Age-related Macular Degeneration

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Presence of at least one large druse >125 microns in diameter due to AMD.
  • BCVA letter score of 35 to 70 letters (inclusive) (Snellen equivalent 6/12 to 6/60 [20/40 to 20/200])

Key Exclusion Criteria

  • Any implanted electrical device(s) including deep brain stimulator, hearing or visual implants (i.e., cochlear implant, auditory brainstem implant, retinal prostheses), and/or cardiac defibrillator/pacemaker.
  • Implanted metallic device within 20 cm of the Treatment electrode (study eye(s)) and/or the grounding electrode (base of the hairline on the back of the neck).
  • Uncontrolled diabetes, defined as glycated haemoglobin (HbA1c) >10% (13.3 mmol/L).
  • Current tobacco or tobacco-related product use or history within the past 5 years of heavy smoking (defined as, on average, more than half a pack of cigarettes per day).
  • Known severe allergy to fluorescein dye.
  • Medical diagnosis of severe dry eye defined as requiring either artificial tears more than six (6) times a day or prescription drops (i.e., Restasis, Xiidra, or Cequa).
  • History of seizure disorders, chronic migraines and/or cluster headaches.
  • History and/or evidence of diabetic retinopathy in either eye as assessed by CF, fundus fluorescein angiography (FA), and OCT, to be confirmed by the Central Reading Centre.
  • Other conditions which pre-dispose to chorioretinal atrophy such as inherited retinal dystrophy (i.e., Stargardt's disease, Best's disease, pattern dystrophy, central areolar choroidal dystrophy, etc.).
  • History and/or evidence of exudative AMD in the study eye as assessed by CF, FA (or OCT-A ), and OCT, to be confirmed by Central Reading Centre.
  • GA involving the foveal centre, as assessed by the Central Reading Centre using AF and OCT.
  • History of intravitreal injections for GA (e.g., Syfovre or Izervay).
  • Treatment with photobiomodulation (PBM) therapy or short pulse laser within 12 months prior to screening.
  • Glaucoma requiring ≥3 medications and/or drops per day, or history of trabeculectomy.
  • History of any kind of intraocular surgery, excluding cataract surgery performed ≥3 months from Screening.
  • History of yttrium aluminium garnet (YAG) laser posterior capsulotomy \<1 month from Screening.
  • Visually significant cataracts and/or visually significant posterior capsular opacification.
  • History of amblyopia.

Recruiting US locations

  • Retina Consultants San Diego

    Poway, CA 92064

    Site contact: Research Coordinator · 858-451-1911 · dcarbajal@rcsd.com

  • Retina Consultants PC

    Manchester, CT 06042

    Site contact: Chris Research Coordinator · 860-646-7704 x113 · cdwy@retinact.com

  • University Retina & Macula Associates

    Lemont, IL 60439

    Site contact: Clinical Research Manager · 708-765-4110 · swheatley@uretina.com

  • Retina Associates of Cleveland

    Beachwood, OH 44122

    Site contact: Diane Research Coordinator · (216) 831-5700 · dweiss@retina-assoc.com

  • Texas Retina Associates

    Fort Worth, TX 76104

    Site contact: Lori Research Coordinator · 817-334-0882 x411 · lmullen@texasretina.com

  • Tyler Retina Research Insitute

    Tyler, TX 75703

    Site contact: Melissa Long Research Coordinator · 903-597-4644 · mlong@tylerretina.com

Study contacts (from the official record)

  • Meredith Mundy · 408-440-7049 · mmundy@i-lumen.com
Microcurrent Stimulation Therapy for Intermediate to Advanced… (NCT06662162) | Bored Studies